Small Molecule drug treatment is one of the main approaches in treating cancer. Until recent years, chemotherapy was the only approach to treat cancer; with its biggest inability is to distinguish between cancer cells and normal cells, thus resulting in significant toxicity and side effects.
In last two decades, there has been a tremendous shift in cancer treatment, from broad-spectrum cytotoxic drugs to targeted therapies. Unlike traditional chemotherapy drugs, targeted drugs can specifically target cancer cells but spare normal cells, hence having high potency and low toxicity.
Cancer Targeted Therapies can be roughly classified into two categories: Small Molecules and Macromolecules/ Biologics (e.g., monoclonal antibodies, polypeptides, antibody–drug conjugates, and nucleic acids).
To date, there are a nearly 100 anti-cancer targeted small molecules approved in the United States and China, with large number under clinical development, targeting kinases, epigenetic regulatory proteins, DNA damage repair enzymes, and proteasomes.
Following are the series of articles which provides the latest updates and insights on Targeted Small Molecule Cancer Drug Development.
1. Small Molecule Kinase Inhibitors
- Kinase Inhibitors – An Overview
- Approved Oncology Targeting Kinase Inhibitors. (86 Molecules)
- Approved Non-Oncology Targeting Kinase Inhibitors. (16 Molecules)
- Kinase Inhibitors in Active Clinical Development – Developers, Pipeline, Target & Cancer Indication. (330 Molecules)
- Kinase Inhibitors in Active Preclinical Development – Developers, Pipeline, Target & Cancer Indication. (244 Molecules)
- Clinical Stage Companies Developing Oncology Targeting Kinase Inhibitors. (227 Companies)
- Preclinical / Early Stage Companies Developing Oncology Targeting Kinase Inhibitors. (122 Companies)
2. Epigenetic Inhibitors
- Epigenetic Inhibitors – An Overview
- Approved Oncology Targeting Epigenetic Inhibitors. (XX Molecules)
- Small Molecule Epigenetic Inhibitors in Active Clinical Development – Developers, Pipeline, Target & Cancer Indication. (XX Molecules)
- Small Molecule Epigenetic Inhibitors in Active Preclinical Development – Developers, Pipeline, Target & Cancer Indication. (XX Molecules)
- Companies Developing Oncology Targeting Epigenetic Inhibitors. (XX Companies)
3. Bcl-2 Inhibitors
- BCL-2 Inhibitors – An Overview
- Approved Oncology Targeting BCL-2 Inhibitors. (XX Molecules)
- Small Molecule BCL-2 Inhibitors in Active Clinical Development – Developers, Pipeline, Target & Cancer Indication. (XX Molecules)
- Small Molecule BCL-2 Inhibitors in Active Preclinical Development – Developers, Pipeline, Target & Cancer Indication. (XX Molecules)
- Companies Developing Oncology Targeting BCL-2 Inhibitors. (XX Companies)
4. Proteasome Inhibitors
- Proteasome Inhibitors – An Overview
- Approved Oncology Targeting Proteasome Inhibitors. (XX Molecules)
- Small Molecule Proteasome Inhibitors in Active Clinical Development – Developers, Pipeline, Target & Cancer Indication. (XX Molecules)
- Small Molecule Proteasome Inhibitors in Active Preclinical Development – Developers, Pipeline, Target & Cancer Indication. (XX Molecules)
- Companies Developing Oncology Targeting Proteasome Inhibitors. (XX Companies)
5. PARP Inhibitors
- PARP Inhibitors – An Overview
- Approved Oncology Targeting PARP Inhibitors. (XX Molecules)
- Small Molecule PARP Inhibitors in Active Clinical Development – Developers, Pipeline, Target & Cancer Indication. (XX Molecules)
- Small Molecule PARP Inhibitors in Active Preclinical Development – Developers, Pipeline, Target & Cancer Indication. (XX Molecules)
- Companies Developing Oncology Targeting PARP Inhibitors. (XX Companies)
6. HEDGEHOG PATHWAY Inhibitors
- HEDGEHOG PATHWAY Inhibitors – An Overview
- Approved Oncology Targeting HEDGEHOG PATHWAY Inhibitors. (XX Molecules)
- Small Molecule HEDGEHOG PATHWAY Inhibitors in Active Clinical Development – Developers, Pipeline, Target & Cancer Indication. (XX Molecules)
- Small Molecule HEDGEHOG PATHWAY Inhibitors in Active Preclinical Development – Developers, Pipeline, Target & Cancer Indication. (XX Molecules)
- Companies Developing Oncology Targeting HEDGEHOG PATHWAY Inhibitors. (XX Companies)
